At a time where vaccine skepticism is growing and the childhood vaccine schedule updated in January, vaccine manufacturers are running into a difficult regulatory review process in the United States. Beyfortus, an extended half-life anti-RSV monoclonal antibody developed by AstraZeneca and sold by Sanofi, has bucked the trend, being approved for preventing hospitalization from RSV in newborns. The drug was only launched in the Fall of 2023.
Beyfortus is a next generation of Synagis, which had been providing premature babies protection against hospitalization for RSV since 1998. Each dose of Synagis is only protected for approximately one month, requiring up to six doses to cover the RSV season. The short half-life made it only cost effective for a small group of newborns.
After several severe RSV seasons and improved confidence in the safety and efficacy of antibodies for RSV, the demand for Beyfortus was overwhelming, far surpassing the expectations and production. Sales of Beyfortus have already crossed $2 billion annually for a product that is only approved for newborns and children with high risk of RSV hospitalization. Additionally, Merck recently received approval for their version of an extended half-life RSV antibody and received initial ACEP recommendation.
Monoclonal antibodies: Immunity, reimagined
Monoclonal antibodies are not new. Since the FDA approved the first monoclonal antibody therapy in 1986, Orthoclone or OKT3 (muromonab-CD3), for use in preventing kidney transplant rejection, these therapies have revolutionized treatment for cancers, autoimmune diseases, and metabolic disorders. In the last decade, they’ve taken center stage with infectious disease control, from Covid-19 to RSV.
Unlike vaccines that train the body to develop its own immune response, monoclonal antibodies provide immediate passive immunity without modifying the immune system in any way. They circulate in the bloodstream and neutralize pathogens or toxins directly, with no waiting for immune memory to develop and clear over a finite period.
This “ready-made” immunity is particularly valuable for infants whose immune systems are immature, elderly adults whose immune responses are weakened, and immunocompromised patients who can’t safely receive live vaccines.
In populations that cannot mount a complete immune response, monoclonal antibodies expand the preventive medicine toolkit.
From infection to inflammation: The next frontier
The success of these RSV medications marks the start of a new era for antibody therapies, one where monoclonal antibodies could prevent not only infectious diseases, but the chronic inflammatory conditions that drive aging and healthcare costs.
Recent scientific breakthroughs reveal that bacterial components like peptidoglycan (PGN), a fundamental part of bacterial cell walls, circulate in the bloodstream as we age. PGN chronically stimulates the immune system, leading to a persistent inflammatory state known as inflammaging.
This inflammation fuels heart disease, diabetes, fat accumulation, Alzheimer’s, autoimmune disorders and cancer.
Researchers are increasingly exploring monoclonal antibodies that can intercept peptidoglycan (PGN) before it activates downstream inflammatory pathways. Rather than killing bacteria outright or suppressing inflammation after it occurs, these approaches aim to neutralize the persistent bacterial fragments that keep the immune system in a heightened, chronic state.
Early preclinical work suggests that PGN‑binding antibodies may function like molecular sponges — capturing and clearing the microbial debris that drives systemic inflammation. By reducing this constant immune stimulation, such strategies could open new avenues for managing aging‑related conditions, from metabolic dysfunction to neurodegenerative decline, by restoring immune balance and alleviating long‑term inflammatory stress.
Public health potential and policy implications: From pandemic readiness to health span extension
If the RSV experience showed that monoclonal antibodies can protect the youngest and most vulnerable, the next phase for the use of these therapeutics may extend that protection across the lifespan.
Imagine preventing sepsis in ICU and surgical patients or reducing dementia risk by limiting neuroinflammation. Monoclonal antibodies could one day serve as preventive biologics that protect against both acute infections and chronic diseases, serving as passive protection that augments the natural immune system.
The global healthcare implications are profound. Chronic inflammatory diseases currently account for three-quarters of healthcare spending. Neutralizing PGN and related bacterial toxins could reduce this burden while improving quality of life and longevity.
For governments and health systems, monoclonal antibodies represent not just another drug class, but a strategic shift toward precision prevention.
Continued investment and increased regulatory flexibility means antibody-based therapies could become key tools for national and global preparedness — offering both immediate protection against emerging infections and long-term benefits against inflammation-driven disease. The past few years have underscored that the old model, to treat disease after it starts, is no longer sustainable. The next frontier in public health will combine the precision of biologics with the preventive intent of vaccines.
As science progresses, governments, investors and healthcare leaders have a unique opportunity to reshape prevention from the ground up. The age of antibody-based prevention has begun, and it promises to redefine what it means to stay healthy.
Photo: User7565abab_575, Getty Images
Jeff Fischer, MBA, President, Longhorn Vaccines and Diagnostics, is responsible for oversight of all non-scientific aspects of the organization to include regulatory affairs. Mr. Fischer co-founded the company and has served as its Chief Financial Officer from 2007-2017. From 1998-2005, Mr. Fischer served as an executive vice president and CFO in the biotechnology industry. He is a former infantry officer in the United States Marine Corps and holds an MBA from the University of Texas at Austin.
This post appears through the MedCity Influencers program. Anyone can publish their perspective on business and innovation in healthcare on MedCity News through MedCity Influencers. Click here to find out how.
